CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 547 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01076192
NCT01076192N/ACompleted
CompareCT.gov

Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA®) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.

AbbVie (prior sponsor, Abbott)·observational·Posted Feb 26, 2010·Updated Jan 6, 2016

In Brief

An observational study for Moderate-to-severe Chronic Plaque Psoriasis. Completed, enrolled 547 participants.

Detailed Summary

The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in Spain.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-severe Chronic Plaque Psoriasis
Countries--
CollaboratorsIMS Health

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2010
Enrollment StartFeb 1, 2010
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 16.3 years ago